Introduction
Prostate cancer is the second most frequent cancerrelated cause of death in males in the United States (Wingo et al., 1995) . Androgen-ablation is standard therapy for prostate cancer because 80% of patients show an initial response to such treatment (Carter and Coey, 1990; McCollough, 1988; Wingo et al., 1995) . However, this therapy is rarely curative, because cancer within an individual patient is heterogeneous, including both androgen-dependent and -independent prostatic cancer cells even before therapy is initiated. The precise mechanism by which prostate cancer cells develop androgen independence is not understood. However, several studies have suggested an increase in the antiapoptotic protein Bcl-2 in hormone-independent prostate cancer (McDonnell et al., 1992; Bromberg and Scher, 1993; Colombel et al., 1993; Krajewska et al., 1996) . An increase in the expression of antiapoptotic proteins that provide cell survival functions may result in progression of the disease and micrometastasis of the cancer. The identi®cation of molecular pathways that will abrogate the induction or function of anti-apoptotic genes may oer insights required for prostate cancer control.
Our recent studies have identi®ed a novel, proapoptotic protein, designated prostate apoptosis response-4 (Par-4), that can sensitize prostate cancer cells to apoptosis Rangnekar, 1998; Sells et al., 1994 Sells et al., , 1997 . The par-4 gene is widely expressed (Rangnekar, 1998; Sells et al., 1997) and is induced by apoptotic stimuli such as intracellular calcium elevators ionomycin or thapsigargin in rat androgen-independent prostate cancer cells or castration in rat ventral prostate (Rangnekar, 1998; Sells et al., 1994 . This gene is not induced by growth stimulation, growth arrest or necrosis, or after castration in rat tissues such as liver or kidneys in which androgen-ablation does not lead to apoptosis (Sells et al., 1994) . The induction of par-4 in rat prostate cells has been found to be speci®cally associated with activators of apoptosis (Rangnekar, 1998; Sells et al., 1994 Sells et al., , 1997 . Most importantly, Par-4 levels are low in the secretory epithelium of the prostate in uncastrated rats, but the levels are elevated in the secretory epithelium of the prostate from castrated rats . Because the secretory epithelial cells undergo apoptosis upon castration, these observations suggest a strong link between Par-4 induction and sensitivity to apoptosis.
The amino acid sequence of Par-4 predicts a protein with a leucine zipper domain at its carboxy terminus (Sells et al., 1994 . Moreover, about 70 amino acids at its carboxy terminus that include the leucine repeat region constitute a death domain homologous to that found in other apoptotic genes such as Fas or tumor necrosis factor-a receptor-1 (Diaz-Meco et al., 1996; Johnstone et al., 1996; Rangnekar, 1998; Sells et al., 1994) . Functionally, Par-4 expression sensitizes cells to apoptosis induced by growth factor starvation or by agents that elevate intracellular Ca 2+ (Diaz-Meco et al., 1996; Sells et al., 1997) . Deletion of the leucine zipper domain results in loss of the pro-apoptotic function of Par-4 protein . Moreover, separate expression of the leucine zipper domain of Par-4 provides a dominant-negative eect by abrogation of the pro-apoptotic function of full-length Par-4 . Also, antisense deoxyoligomer-mediated inhibition of Par-4 expression abrogates apoptosis . Together, these data suggest that par-4 induction is apoptosis-response-speci®c, and that par-4 is causally involved in apoptosis.
Prostate cancer cells can resist apoptotic cell death by up-regulation of the anti-apoptotic protein Bcl-2 (Colombel et al., 1993) . The bcl-2 gene was identi®ed because of its involvement in human follicular B-cell lymphomas, in which it confers neoplastic cell expansion as a consequence of prolonged cell survival Yang and Korsmeyer, 1996) . Bcl-2 protein was thought to function by directly binding and inhibiting the function of the pro-apoptotic protein Bax. However, recent studies suggest that while an in vivo competition exists between Bax and Bcl-2, the two proteins may function independently to regulate cell death (Knudson and Korsmeyer, 1997; St Clair et al., 1997; Ishibashi et al., 1998) . Bcl-2 and Bax proteins form channels in the mitochondrial membrane and regulate the ion potential and release of the apoptotic marker protein cytochrome C from the mitochondria (Yang and Korsmeyer, 1996) . Moreover, Bcl-2 protects against apoptosis after mitochondrial leakage of cytochrome C into the cytoplasm (Rosse et al., 1998; Zhivotovsky et al., 1998) . In the adult prostate, Bcl-2 protein is expressed in the basal cell compartment of normal and hyperplastic tissue, but neither in the secretory compartment of such tissue nor in advanced cancerous tissue (Krajewska et al., 1996) . The incidence and level of Bcl-2 expression is higher in androgenindependent prostate cancer as compared to androgendependent prostate cancer (Colombel et al., 1993; McDonnell et al., 1992; Krajewska et al., 1996) , suggesting that prostate cancer cells may resist androgen-ablation inducible apoptosis by Bcl-2 upregulation. Androgen withdrawal results in downregulation of Bcl-2 expression and subsequent apoptosis of androgen-dependent normal or neoplastic prostate cells (McDonnell et al., 1992) . Moreover, ectopic overexpression of Bcl-2 provides prostatic cells resistance to apoptotic death in cell culture and in vivo (Rao et al., 1990) . Bcl-2 may confer resistance to apoptosis in prostate cancer cells by preventing nuclear import of the pro-apoptotic protein p53 (Beham et al., 1997) . These studies strongly suggest that Bcl-2 levels regulate apoptosis in the normal and neoplastic prostate. Downregulation of Bcl-2 may therefore serve to sensitize prostatic cells to apoptosis. The present study investigated downregulation of Bcl-2 as a mechanism for Par-4-mediated apoptosis.
Results

Par-4 downregulates Bcl-2 protein levels
In the course of studies to understand the mechanism by which Par-4 may induce apoptosis, we determined whether Par-4 altered the expression of the antiapoptotic protein Bcl-2. To ascertain that the results were not biased by cell type-speci®c factors, we used two dierent cell backgrounds (NIH3T3 or PC-3) and either inducible or constitutive overexpression of Par-4. NIH3T3/tetO-Par-4 cells or NIH3T3/tetO-DCTH cells that contained the tetracycline-regulated expression system for full-length Par-4 or the Par-4 carboxy terminus deletion mutant DCTH, respectively, were grown either in the presence or absence of tetracycline. The DCTH mutant construct, which does not confer pro-apoptotic function, served as a control in these experiments. The absence of tetracycline led to induction of the Par-4 constructs, as evident from the increase in the 38 kDa Par-4 species from the tetO-Par-4 construct or the 18 kDa DCTH species from the tetO-DCTH construct (Figure 1a ). Endogenous Par-4 (38 kDa species) was unaltered by tetracycline withdrawal from NIH3T3/tetO-DCTH cells. Interestingly, withdrawal of tetracycline resulted in about 70% reduction in Bcl-2 (26 kDa) levels in NIH3T3/tetOPar-4 cells that were grown in serum-containing growth medium ( Figure 1a ). On the other hand, NIH3T3/tetO-DCTH cells that were induced to express the DCTH mutant ( Figure 1a ) did not show a decrease in Bcl-2 levels. Moreover, induction of Par-4 or DCTH mutant by tetracycline withdrawal did not cause a reduction in Bax (21 kDa) protein levels ( Figure 1a) . Thus, induced expression of Par-4, which shows pro-apoptotic functions, but not the DCTH mutant that is nonapoptotic, causes a decrease in Bcl-2 protein levels.
To study the eect of Par-4 on Bcl-2 levels in prostate cancer cells, we used PC-3 transfectants PC-3/ CMV-Par-4 that overexpressed Par-4 from a constitutive cytomegalovirus (CMV)-promoter or PC-3/vector for control. Each of these cell lines was obtained by pooling about 200 transfected clones. Data for two dierent pools of transfected clones is shown in Figure  1a . Relative to PC-3/vector cells, PC-3/CMV-Par-4 cells showed a fourfold increase in Par-4 levels but a 70% decrease in Bcl-2 expression ( Figure 1a ). Together, these experiments indicated that Par-4 causes a reduction in the cellular levels of Bcl-2 protein.
We also studied the eect of enforced Bcl-2 expression on endogenous levels of Par-4, by using PC-3 transfectants PC-3/Bcl-2 that overexpressed Bcl-2 from a constitutive splenic focus-forming virus (SFFV)-promoter or PC-3/vector for control. Each of these cell lines was obtained by pooling about 150 transfected clones. As expected, PC-3/Bcl-2 cells but not PC-3/vector cells, showed strong expression of ectopic Bcl-2 ( Figure 1b ). PC-3/Bcl-2 and PC-3/vector cells showed similar levels of endogenous Par-4 protein ( Figure 1b ). These data indicated that the level of endogenous Par-4 protein is unaected by an increase in the level of Bcl-2 protein.
Par-4-dependent apoptosis is inhibited by coexpression of Bcl-2
To determine the relevance of the reduction in Bcl-2 levels in Par-4-dependent apoptosis, we transiently transfected MEFs with vector alone, CMV-Par-4 plus vector, CMV-Bcl-2 plus vector, or CMV-Par-4 plus CMV-Bcl-2, and either examined whole-cell protein extracts for expression of Par-4 and Bcl-2 proteins or maintained the cells for 24 h in the presence or absence of serum. The rationale was that if Par-4-mediated reduction in Bcl-2 levels was causally important for sensitization of the Par-4 transfectants to apoptosis, replenishment of Bcl-2 levels in the Par-4 transfectants would provide protection from apoptosis. As seen in Figure 1c , transfection with CMV-Par-4 plus vector resulted in an increase in the level of Par-4 protein over the endogenous level seen in MEFs that were transfected with vector alone or Bcl-2 plus vector. Cotransfection with CMV-Bcl-2 did not alter the level of Par-4 expression in the CMV-Par-4 transfected MEFs (Figure 1c ). These data suggested that enforced Bcl-2 expression does not alter the level of ectopic Par-4 protein. Figure 1 Par-4 overexpression results in a decrease in Bcl-2 protein levels. (a) Whole-cell protein extracts were prepared from NIH3T3/tetO-Par-4 or NIH3T3/tetO-Par-4-DCTH transfectants grown in serum-containing medium in the presence (+) or absence (7) of tetracycline (tet; 2 mg/ml) for 24 h or from PC-3/vector or PC-3/CMV-Par-4 transfectants. The proteins were examined for Par-4, Bcl-2 (with D21 antibody), Bax, or b-actin expression by Western blot analysis. Note that Par-4 but not DCTH or vector inhibits Bcl-2 (26 kDa) expression. The 30 kDa protein species seen above Bcl-2 (26 kDa band) in NIH3T3/tetO-Par-4 cells grown in the absence of tet was not reproduced in multiple experiments. Downregulation of Bcl-2 by Par-4 overexpression in NIH3T3 or PC-3 background was reproducible in four separate experiments. (b) Whole-cell protein extracts were prepared from pools of PC-3 clones stably transfected with either vector or SFFV-Bcl-2 and subjected to Western blot analysis with the Bcl-2 100 antibody, Par-4 antibody, or b-actin antibody. The band for ectopic (human) Bcl-2 protein is indicated. The weaker band below the ectopic Bcl-2 band represents endogenous Bcl-2. The band for ectopic Bcl-2 is expected to include the Flag sequence from the construct, and migrates correspondingly slower than endogenous Bcl-2. (c and d) MEFs were transiently transfected with vector, CMV-Par-4 plus vector, CMV-Bcl-2 plus vector, or CMV-Par-4 and CMV-Bcl-2, and 24 h later the cells were either harvested for whole-cell protein extracts that were subjected to Western blot analysis with Bcl-2 100 antibody, Par-4 antibody or b-actin antibody (c), or maintained either in the presence or absence of serum for 24 h and examined for apoptosis (d). Apoptosis in the culture was quanti®ed by terminal transferase dUTP-nick end labeling (TUNEL). About 300 cells were scored for TUNEL-positive nuclei in each experiment to quantify apoptosis. TUNEL results shown are a mean of three separate experiments; error bars indicate+standard deviation When grown in the presence of serum, none of the transfected cultures showed 42% apoptosis ( Figure  1d ). By contrast, when grown in the absence of serum, Par-4 plus vector transfectants showed a signi®cant increase (P50.001 by Student t-test) in apoptosis over that seen with vector transfectants (Figure 1d ). On the other hand, Par-4 and Bcl-2 cotransfectants showed apoptosis similar to that seen with vector alone (Figure  1d ). Cells expressing Bcl-2 plus vector were highly resistant to apoptosis caused by serum withdrawal (Figure 1d) , indicating that the Bcl-2 protein was functional in the assay. These data suggest that Bcl-2 overexpression can rescue the cells from Par-4-dependent sensitization to apoptosis.
Par-4 and Bcl-2 expression patterns in benign and cancerous areas of prostate tumors Because Par-4 serves as a pro-apoptotic protein and Bcl-2 serves as an anti-apoptotic protein, we examined whether these two proteins show inverse expression patterns in prostate cancer tissue, in which the cells are expected to undergo apoptosis (Wheeler et al., 1994; Berges et al., 1995; Aihara et al., 1995; Tu et al., 1996) . The expression of Par-4 and Bcl-2 proteins in specimens from prostate cancer patients was examined by immunohistochemistry. We tested a total of 26 primary prostate cancer specimens from T2B stage cancer patients and seven specimens of lymph node metastasis of prostate cancer cells. Each of the 26 primary tumors was examined for expression of these proteins in the benign and cancerous areas within the specimens. The data are summarized in Table 1 , and representative illustrations are shown in Figures 2 and  3 . The benign areas of all 26 prostate tumors showed Par-4 expression in both the basal and secretory cell compartments (Figure 2 ). On the other hand, Bcl-2 expression in the benign areas of these 26 tumors was mainly restricted to the basal cell compartment ( Figure  2 ). In the cancerous areas of the 26 primary tumors or the seven metastatic tumors, Par-4 expression was intense, but Bcl-2 expression was undetectable (Figures  2 and 3) . Interestingly, Par-4 showed both nuclear and cytoplasmic localization in the benign areas (Figure 2 ), mainly cytoplasmic localization in primary advanced cancers (Figures 2 and 3) , and perinuclear/nuclear localization in metastatic tumors (Figure 3) . The CWR22 xenograft is an excellent model system that closely emulates the clinical progression of human prostate cancer from an androgen-dependent to an androgen-independent state (Nagabhushan et al., 1996) . CWR22 tumors grown in the presence of testosterone pellets in intact nude mice do not show apoptosis but are apt to undergo involution upon castration and removal of the testosterone pellets (Nagabhushan et al., 1996) . We subjected six xenografts each of androgen-dependent CWR22 or recurrent androgen-independent CWR22R tumors to immunohistochemical analysis for Par-4 and Bcl-2 expression. Par-4 but not Bcl-2 expression was detected in all the CWR22 tumors (Figure 4) . By contrast, cell compartments containing either Par-4 or Bcl-2, but never both, were detected in all the CWR22R tumors (Figure 4) . When a total of about 250 cells that expressed Bcl-2 in the CWR22R tumors were scored, none of them showed Par-4 expression. Thus, the CWR22R tumors contained areas showing mutually exclusive expression of Bcl-2 or Par-4.
Discussion
Previous studies have shown that exogenous apoptotic insults such as androgen withdrawal from prostate cancer cells cause a reduction in the levels of the antiapoptotic protein Bcl-2 (McDonnell et al., 1992) . The molecular pathway(s) leading to Bcl-2 downmodulation is, however, not characterized. Par-4 protein is induced upon androgen-ablation ) and the present study indicated that Par-4 causes downmodulation of endogenous Bcl-2 protein levels in ®broblasts (NIH3T3) and prostate cancer (PC-3) cells. Transient coexpression of ectopic Bcl-2 rescued ®broblast cells from Par-4-dependent apoptosis induced by withdrawal of serum growth factors, suggesting that Bcl-2 downmodulation is required for Par-4-dependent apoptosis. The present observation on the protection of fibroblasts from Par-4-dependent apoptosis by coexpression of ectopic Bcl-2 from the heterologous CMV promoter is consistent with that recently reported by using ectopic Bcl-2 coexpression with the SFFV promoter (Berra et al., 1997) . The fact that endogenous Bcl-2 is downregulated by Par-4 in actively growing ®broblasts or prostate cancer cell cultures in the presence of serum (i.e. in the absence of apoptosis-inducing stimuli) suggests that the suppression of endogenous Bcl-2 levels by Par-4 is not sucient by itself to induce apoptosis. These observations corroborate the inability of Par-4 to cause apoptosis by itself in diverse cell types and the requirement of a coactivating apoptotic signal(s) for Par-4 to augment apoptosis Diaz-Meco et al., 1996; Rangnekar, 1998; Sells et al., 1997) . Because Par-4 is upregulated and Bcl-2 is downregulated after androgen ablation, these ®ndings suggest that Par-4 is an important component of the molecular pathway leading to Bcl-2 downregulation and apoptosis. Thus, the present study has identi®ed Bcl-2 as a target of Par-4 action and suggested a mechanism by which Par-4 may augment apoptosis upon growth factor withdrawal.
In agreement with observations from previous studies (Krajewska et al., 1996; McDonnell et al., 1992), Bcl-2 protein expression was detected in the basal cell compartment of benign tissue but not in cancerous tissue. By contrast, Par-4 was detected in the basal and secretory compartment of benign tissue and in primary and metastatic prostate cancers. Because the secretory epithelium within benign areas of prostate tumors or the epithelial cells constituting advanced or metastatic prostate tumors can undergo apoptosis, whereas the basal cells within benign areas of the tumors do not undergo apoptosis (Aihara et al., 1995; Berges et al., 1995; Colombel et al., 1993; Tu et al., 1996; Wheeler et al., 1994) , the relationship between Par-4 and Bcl-2 expression noted in the present study correlates with the apoptotic potential of the tumor cells.
CWR22 tumors maintained in intact mice in the presence of testosterone pellets showed expression of Par-4 but not Bcl-2, consistent with the fact that they are susceptible to apoptosis. By contrast, CWR22R tumors that arose from androgen-independent cells that survived androgen withdrawal express either Par-4 or Bcl-2, but never both within the same cell. The use of consecutive sections taken from multiple CWR22R tumors enabled us to compare the histological areas and ascertain mutually exclusive expression of Par-4 and Bcl-2 within the same cell. Interestingly, the bulk (490%) of each of the six CWR22R tumors examined expressed Par-4 but not Bcl-2. This implied that the progenitor cells that produced this recurrent tumor could resist apoptosis after androgen withdrawal despite the continued expression of Par-4 and lack of Bcl-2, suggesting that other protective anti-apoptotic Figure 3 Immunohistochemical analysis of Par-4 and Bcl-2 in primary or metastatic prostate tumors. Prostate tumor specimens representing primary T2B tumors (a, b, c) or lymph node metastasis (d, e, f) were immunostained with Par-4 antibody (a, d), Bcl-2 antibody (b, e), or pre-immune antibody (c, f). Brown staining with DAB is indicative of positivity; methyl green was used as counterstain. The magni®cation (Mag) and type of immunostaining is indicated in each panel mechanisms are activated in these cells. The foci that lack Par-4 but expressed Bcl-2 represent 510% of the cells within the CWR22R tumors. These foci most likely contain a variant population that was selected after androgen withdrawal because the CWR22 tumor cells, from which the CWR22R tumors arose, were all Bcl-2-negative and Par-4-positive. The presence of Bcl-2 in these foci may confer a selective growth advantage that might result in an expansion of the Bcl-2-positive compartments within the CWR22R tumor. Future studies should identify the anti-apoptotic mechanisms that are upregulated in a majority of the cells of the CWR22R tumors and also the mechanism(s) that may have led to the downmodulation of Par-4 in the Bcl-2-positive foci.
Although Par-4 has been characterized as a transcriptional repressor (Johnstone et al., 1996) , it is not known whether it can directly contact DNA. Alternately, a cytoplasmic role for Par-4 has been suggested by interaction with, and inactivation of, protein kinase C-z (Diaz-Meco et al., 1996) . Consistent with these observations and suggesting both cytoplasmic and nuclear roles for Par-4, the present study detected Par-4 in both the cytoplasm and nucleus of benign tumors, in the cytoplasm of primary tumors, and in the perinuclear/nuclear compartment in metastatic tumors. Downmodulation of endogenous Bcl-2 by Par-4 (this study) and rescue of cells from Par-4 action by Bcl-2 overexpression with the CMV (this study) or SFFV (Berra et al., 1997) promoter may suggest transcriptional regulation of Bcl-2 by Par-4; however, this hypothesis needs to be formally tested. Studies are underway to address whether the regulation of Bcl-2 by Par-4 occurs at the transcription level and whether Bcl-2 is a direct or indirect target of Par-4.
Materials and methods
Plasmids and cell lines
The pRc-CMV-Par-4 construct that contains the entire coding region of Par-4 under the control of the CMV promoter in the expression vector pRc-CMV (Invitrogen Corp., Inc., San Diego, CA, USA) has been described . The EcoR1 fragment of par-4 cDNA from pCB6 + /Par-4 or pRc-CMV-Par-4.DCTH was inserted into vector pUHD10-3 which contains the tetracycline-regulated promoter-operator system (Gossen et al., 1995) , to obtain constructs tetO-Par-4 or tetO-DCTH, respectively. NIH3T3.L1 cells containing the pUHD15-1neo plasmid for expression of the tetracycline activator were purchased from Clonetech Corp. (Palo Alto, CA, USA). NIH3T3/tetO-Par-4 or NIH3T3/tetO-DCTH cells were obtained by transfection of NIH3T3.L1 cells with pUHD10-3/tetO-Par-4 or pUHD10-3/tetO-DCTH plasmid, respectively. Vector pSFFV-Neo (Hunter et al., 1996) and human Bcl-2 expression construct pSFFV-Neo/ Bcl-2-Flag, in which bcl-2 cDNA is placed under the control of the SFFV promoter, were from Gabriel Nunez (University of Michigan, Ann Arbor, MI, USA). The pRc-CMV-Bcl-2 expression construct for human Bcl-2 was from John Reed (Burnham Institute, La Jolla, San Diego, CA, USA). PC-3 cells that stably express either pCB6 + empty vector or pCB6 + /Par-4 have been described . Mouse embryo ®broblasts (MEFs) were kindly provided by Tyler Jacks (Massachusetts Institute of Technology, Cambridge, MA, USA).
Prostate tumors
The androgen-dependent CWR22 tumors were from intact nude mice implanted with testosterone pellets (Nagabhushan et al., 1996) . To obtain CWR22R tumors, the testosterone pellets were removed and the nude mice were castrated. This resulted in rapid shrinkage of the tumors owing to apoptosis of the androgen-dependent cells. However, after maximal involution of the tumor when the androgen-dependent cells had been eliminated, the androgen-independent cells grew to form the recurrent CWR22R tumors (Nagabhushan et al., 1996) . Paranembedded xenografts of androgen-dependent CWR22 or recurrent, androgen-independent CWR22R tumors (Nagabhushan et al., 1996) were kindly provided by Thomas Pretlow (Case Western Reserve Medical Center, Cleveland, OH, USA). Freshly frozen prostatic tissue obtained from prostate cancer patients was formalin-®xed, then paranembedded, and provided for the study by the Markey Cancer Center Tumor Bank, University of Kentucky, Lexington, KY, USA with the approval of the Internal Review Board.
Immunohistochemical analysis of prostatic tumor specimens
The paran-embedded tissues were sectioned and subjected to immunohistochemical analysis with the Par-4 polyclonal antibody (R334 from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), Bcl-2 monoclonal antibody (M0887, Dako Corp., Carpinteria, CA, USA or a pre-immune antibody as described .
Western blot analysis for Par-4
Whole-cell protein extracts were prepared in Laemmli's buer and 20 mg amounts of extract proteins were resolved by SDS-polyacrylamide gel electrophoresis, then transferred to nylon membranes as described and subjected to enhanced chemoluminescence-Western blot analysis (according to the protocol supplied by the manufacturers, Amersham Corp., IL, USA) for Par-4, Bcl-2, Bax, or b-actin. The following antibodies from Santa Cruz Biotechnology, Inc., were used for Western analysis: Bcl-2 monoclonal antibody 100 (human Bcl-2-speci®c); Bcl-2 polyclonal antibody DC21 (mouse, rat and human Bcl-2-reactive); and Bax polyclonal antibody N-20 (mouse, rat and human Bax-reactive). The b-actin antibody was from Sigma Chemical Co. (St Louis, MO, USA).
Transfection of cells and apoptosis assays
Cells were transfected with plasmid DNA by using lipofection as described . For cotransfection experiments, equal amounts of both plasmids (CMVPar-4 and CMV-Bcl-2 or vector) were used. Stably transfected PC-3 cells were selected with G418 sulfate (300 mg/ml), and stably transfected NIH3T3.L1 cells were selected with both hygromycin (200 mg/ml) and G418 sulfate (200 mg/ml). The apoptotic cells were quanti®ed as described .
